Unbiased CSF Proteomics in Patients With Idiopathic Normal Pressure Hydrocephalus to Identify Molecular Signatures and Candidate Biomarkers.
de Geus MB. et al, (2025), Neurology, 104
A compilation of reported alterations in the cerebrospinal fluid proteome in Alzheimer's disease.
de Geus MB. et al, (2025), Brain Commun, 7
Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers.
Cheng Y. et al, (2025), Brain Commun, 7
Basic Science and Pathogenesis
Abey AS. et al, (2024), Alzheimer's & dementia : the journal of the Alzheimer's Association, 20
Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols.
Luthi-Carter R. et al, (2024), Sci Rep, 14
Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
Yang H-S. et al, (2024), Brain, 147, 2158 - 2168
BERNN: Enhancing classification of Liquid Chromatography Mass Spectrometry data with batch effect removal neural networks.
Pelletier SJ. et al, (2024), Nat Commun, 15
Interrogation of the human cortical peptidome uncovers cell-type specific signatures of cognitive resilience against Alzheimer's disease.
Morgan GR. and Carlyle BC., (2024), Sci Rep, 14
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease.
Arnold SE. et al, (2024), Alzheimers Dement (N Y), 10
Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease.
Trombetta BA. et al, (2024), Alzheimers Dement (N Y), 10
Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer's disease in a large clinical sample.
de Geus MB. et al, (2023), Sci Rep, 13
Correction to "Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer's Disease".
Quinn JP. et al, (2023), J Am Soc Mass Spectrom, 34, 2435 - 2436
Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer's Disease.
Quinn JP. et al, (2023), J Am Soc Mass Spectrom, 34, 649 - 667
Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.
Kivisäkk P. et al, (2023), Front Neurol, 14
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.
Audrain M. et al, (2023), Brain Commun, 5
Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
Kivisäkk P. et al, (2022), Alzheimers Res Ther, 14
Plasma IL-12/IFN-γ axis predicts cognitive trajectories in cognitively unimpaired older adults.
Yang H-S. et al, (2022), Alzheimers Dement, 18, 645 - 653
Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment.
Kivisäkk P. et al, (2022), Brain Commun, 4
Proteomic characterization of post-mortem human brain tissue following ultracentrifugation-based subcellular fractionation.
Kandigian SE. et al, (2022), Brain Commun, 4